我院2010-2013年口服降糖药应用分析

发布时间：2018-05-17 04:15

本文选题：口服降糖药 + 销售金额　；参考：《中国药房》2015年05期

【摘要】：目的:为临床合理使用口服降糖药(OHAs)提供参考。方法:采用回顾性分析方法,对我院2010-2013年临床应用的OHAs品种、销售金额、用药频度(DDDs)、日均费用(DDC)等进行统计、分析。结果:我院2010-2013年OHAs的销售金额总体呈下降趋势,销售金额排序列前4位的是阿卡波糖、二甲双胍、瑞格列奈和格列美脲,其4年销售金额之和占OHAs总销售金额的67.73%;DDDs排序列前4位的依次为二甲双胍、阿卡波糖、格列齐特和瑞格列奈;格列齐特和二甲双胍的DDC均较低。二肽基肽酶-4抑制剂近两年开始进入临床,且增长快速。结论:我院OHAs的临床应用基本合理,高效、安全、依从性好的药物更受临床青睐。
[Abstract]:Objective: to provide reference for the rational use of oral hypoglycemic drug OHAs. Methods: retrospective analysis method was used to analyze the clinical application of OHAs in our hospital from 2010 to 2013, such as the variety of OHAs, the amount of money sold, the frequency of drug use and the daily average cost. Results: the sales amount of OHAs in our hospital from 2010 to 2013 showed a general downward trend. The top 4 items in the sales amount order were acarbose, metformin, repaglinide and glimepiride. The sum of the four years' sales amount accounted for 67.73% of the total sales amount of OHAs, and the DDC of Gliclazide and metformin were lower than those of metformin, acarbose, gliclazide and rieglinide in the order of the first 4 places in the order of the total sales amount of OHAs in the order of metformin, acarbose, gliclazide and rieglinide. Dipeptidyl peptidase-4 inhibitors began to enter clinical practice in the last two years and increased rapidly. Conclusion: the clinical application of OHAs in our hospital is reasonable, effective, safe and compliant.
【作者单位】：上海交通大学附属第一人民医院临床药学科;大连医科大学临床药学系;上海交通大学附属第一人民医院信息科;
【分类号】：R95

【参考文献】